title: Transforming growth factor-β1 treatment of oral cancer induces epithelial-mesenchymal transition and promotes bone invasion via enhanced activity of osteoclasts.
abstract: This study investigates relationships between EMT and bone invasion by OSCC. Three OSCC cell lines, SCC25, HN5, and Tca8113 were artificially induced to display EMT by adding 5 ng/mL of TGF-β1 to culture media for 1-3 days. Cell morphology and phenotypic changes was examined by immunocytochemical staining of CK and VIM. EMT markers, cell-invasion factors, and osteoclast-related molecules were analysed at mRNA, gelatine and protein levels by real-time PCR, gelatine zymography and Western blotting respectively. Mature osteoclasts differentiated from Raw264.7 cells were treated by conditioned medium (CM) of OSCC cells with/without TGF-β1. Immunohistochemistry was performed to validate proteins of CK, VIM, E-cad and Snail1 in OSCC tissue samples with bone invasion. Results showed minimal staining of VIM was found in SCC25 and HN5, while Tca8113 cells stained strongly. EMT markers Twist1 and N-cad were up-regulated; Snail1 and E-cad down-regulated in all cells. Of factors associated with invasion, MMP-2 was unchanged and MMP-9 increased in SCC25 and Tca8113, while MMP-2 was increased and MMP-9 unchanged in HN5. For osteoclast-related molecules, both MT1-MMP and RANKL were up-regulated, while OPG was down-regulated in all cells. CM of OSCC cells pre-treated with TGF-β1 showed to prolong survival of osteoclasts up to 4 days. All target molecules were validated in OSCC samples of bone invasion. These findings suggest that TGF-β1 not only induces EMT to increase the capacity of OSCC for invasion, but also promotes factors which prolong osteoclast survival. TGF-β1 may enhance the ability of MMP2/9 in resorbing bone and favouring invasion of cancer cells.
authors: Schools of Dentistry, and Medical Science, Griffith Health Institute, Griffith University, Parklands Drive, Southport, Gold Coast, QLD, 4222, Australia.
authors: Jingjing
authors: J
authors: Quan
authors: Moustafa
authors: M
authors: Elhousiny
authors: Newell W
authors: NW
authors: Johnson
authors: Jin
authors: J
authors: Gao
mesh_terms: D001483:Base Sequence; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary; D018920:Coculture Techniques; D017931:DNA Primers; D058750:Epithelial-Mesenchymal Transition / Q000187:drug effects*; D006801:Humans; D007150:Immunohistochemistry; D009062:Mouth Neoplasms / Q000188:drug therapy* / Q000473:pathology; D010010:Osteoclasts / Q000166:cytology*; D060888:Real-Time Polymerase Chain Reaction; D053773:Transforming Growth Factor beta1 / Q000627:therapeutic use*
chemical_list: D017931:DNA Primers; D053773:Transforming Growth Factor beta1
references: Hepatology. 2009 Nov;50(5):1464-74
references: 19821482
references: Cancer Metastasis Rev. 2006 Dec;25(4):541-9
references: 17180711
references: Nat Genet. 2001 Oct;29(2):117-29
references: 11586292
references: Mol Cancer. 2010 May 26;9:122
references: 20504320
references: Br J Oral Maxillofac Surg. 2011 Apr;49(3):182-5
references: 20462676
references: Cancer Metastasis Rev. 2012 Jun;31(1-2):209-19
references: 22101806
references: EMBO J. 2003 May 15;22(10):2318-23
references: 12743026
references: Biochim Biophys Acta. 2010 Jan;1803(1):55-71
references: 20080133
references: Anticancer Res. 2010 Jul;30(7):2615-23
references: 20682990
references: Bone. 2011 Jan;48(1):44-53
references: 20601294
references: Clin Exp Metastasis. 2008;25(6):601-10
references: 18535913
references: Head Neck. 2011 May;33(5):708-13
references: 21117177
references: Head Neck. 2004 Oct;26(10):861-9
references: 15390204
references: Pathology. 2012 Apr;44(3):221-7
references: 22406484
references: Future Oncol. 2009 Oct;5(8):1129-43
references: 19852726
references: Cancer Res. 2010 Nov 1;70(21):8607-16
references: 20959474
references: Ann Surg Oncol. 2009 Jul;16(7):1997-2005
references: 19412634
references: Cell. 2010 Apr 2;141(1):52-67
references: 20371345
references: J Mammary Gland Biol Neoplasia. 2010 Jun;15(2):169-90
references: 20467795
references: Bone. 2011 Jan;48(1):6-15
references: 20643235
references: Cancer Res. 2011 Jan 1;71(1):175-84
references: 21084275
references: Bone. 2008 Jul;43(1):7-18
references: 18486584
references: J Pathol. 2004 Aug;203(4):927-32
references: 15258995
references: Bone. 2007 Dec;41(6):912-27
references: 17945547
references: Bone. 2011 Jan;48(1):23-9
references: 20699127
references: Mol Cell Biol. 2009 Jul;29(13):3722-37
references: 19414595
references: Bone. 2011 Jan;48(1):37-43
references: 20670698
references: Cell Res. 2009 Jan;19(1):89-102
references: 19050696
references: Cancer Res. 2010 Jul 1;70(13):5558-66
references: 20551048
references: Cell Res. 2008 Aug;18(8):858-70
references: 18645583
references: Cancer Treat Rev. 2010 Nov;36 Suppl 3:S6-S10
references: 21129612
references: Int J Oncol. 2010 Jun;36(6):1387-94
references: 20428761
references: Cancer. 2011 Oct 1;117(19):4460-7
references: 21437887
references: Int J Oncol. 2001 Apr;18(4):669-81
references: 11251160
references: Int J Oncol. 2010 Sep;37(3):663-8
references: 20664935
references: J Biol Chem. 2006 Dec 1;281(48):36846-55
references: 17018528
references: Oncogene. 2005 Aug 29;24(37):5764-74
references: 16123809
references: J Oral Pathol Med. 2000 May;29(5):232-40
references: 10801041